Why biological data matters more in AI drug discovery

GSK has announced a research collaboration with Relation Therapeutics worth up to $110 million, aimed at enhancing their existing work in AI-assisted drug discovery. Under the agreement, Relation will generate large-scale datasets measuring how human cells respond to genetic changes and drug interventions, which will be used to train AI models to identify potential drug targets. This collaboration builds on earlier agreements between GSK and Relation focused on fibrotic diseases and osteoarthritis, utilizing observational studies to create two functional disease datasets for analysis using Relation’s Lab-in-the-Loop platform.